Heparin-Induced Thrombocytopenia Test Using Prothrombin Fragment F1+2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting heparin-induced thrombocytopenia (HIT) are not suitable for conventional laboratories and require complex manual implementation, and they fail to accurately assess the procoagulant status of patients, which is crucial for identifying acute thrombotic risks.
Innovation Solution
A method that involves mixing a patient's body fluid sample with a platelet-containing reagent and a PF4-binding polysaccharide or polyanion, followed by incubation and determination of prothrombin fragment F1+2 levels to assess the presence of anti-PF4/heparin complex antibodies and the patient's procoagulant status, allowing for the identification of patients at high risk of thrombotic events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If functional test principles are used to detect anti-PF4/heparin complex antibodies, then diagnostic accuracy is improved, but the complexity of manual processing increases and automation becomes difficult
Solution Approach 1:
The patent extracts and measures a specific functional marker (prothrombin fragment F1+2) from the complex platelet activation process. By focusing on this single measurable parameter that directly indicates thrombin generation, the method simplifies the assessment of platelet activation while maintaining diagnostic accuracy for HIT detection
Solution Approach 2:
The test system uses a universal reaction mixture containing platelets, heparin, and PF4 that can detect both the presence of anti-PF4/heparin antibodies and assess procoagulant status simultaneously. This multi-functional approach eliminates the need for separate tests and enables automation through standardized protocols
2Measurement precision
If existing functional tests are implemented, then detection of anti-PF4/heparin complex antibodies is achieved, but assessment of procoagulant status and acute thrombotic risk is not provided
Solution Approach 1:
The patent introduces F1+2 measurement as a feedback parameter that provides real-time information about thrombin generation and procoagulant activity in the reaction mixture. This feedback mechanism allows simultaneous detection of antibodies and assessment of acute thrombotic risk, completing the diagnostic information gap
Solution Approach 2:
The test performs preliminary assessment of procoagulant status by measuring F1+2 levels before clinical thrombotic events occur. This preliminary action enables early identification of patients at high risk, allowing preventive intervention before actual thrombotic complications develop
3Measurement precision
If serotonin release test or HIPA test is used, then platelet activation can be detected, but the tests require complex manual processing and cannot be automated
Solution Approach 1:
The patent replaces manual centrifugation and radioactive material handling with a simplified reaction mixture approach that uses automated platelet-rich plasma preparation and direct optical or chemical detection of F1+2. This substitution of mechanical and radioactive methods with automated biochemical assays enables full automation while maintaining detection precision
Solution Approach 2:
The test changes the measurement parameter from serotonin release or aggregation (which require complex processing) to F1+2 concentration, a parameter that can be measured directly in the reaction mixture using standardized assays. This parameter change enables automation through robotic liquid handling and automated detection systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a functional and automated test for detecting anti-PF4/heparin complex antibodies and effectively assesses the procoagulant status, enabling the identification of patients at high risk of thrombotic events, thereby improving diagnostic accuracy and safety.
Implementation Method 1
Affected patients produce antibodies that bind a complex of heparin and platelet factor 4 (PF4), so-called anti-PF4/heparin complex antibodies. In vivo, the antibody-bound PF4/heparin complex binds to the platelet surface and causes platelet activation.
Implementation Method 2
the quantitative determination of prothrombin fragment F1+2 (F1+2) in a reaction mixture containing the sample to be examined, platelets, and heparin... can be used to determine whether the sample contains anti-PF4/heparin complex antibodies... Samples containing anti-PF4/heparin complex antibodies apparently cause the formation of thrombin in the reaction mixture, so that an increased amount of the prothrombin fragment F1+2, which is formed during the formation of thrombin
Data Source
AI summary
The present invention relates to a functional, easily automated test for detecting heparin-induced thrombocytopenia (HIT). The formation of prothrombin fragment F1+2 in the reaction mixture is measured.